New data from indicates that AstraZeneca’s Symbicort shows promise in treating mild asthma.
Abstracts will be presented at the American Thoracic Society 2019 International Conference this week in Dallas. The drug is now used in treating more severe breathing disorders such as smoking-related COPD.
Findings will be discussed from Novel START, an open-label trial designed to reflect real-world practice, assessed the effectiveness of Symbicort Turbuhaler as a potential anti-inflammatory reliever taken as-needed, compared with two of the most commonly used treatment regimens in mild asthma.
AstraZeneca will also present new science supporting its biologics portfolio and pipeline.
Tom Keith-Roach, Senior Vice President, Respiratory, said: “We look forward to sharing the results from the Novel START trial which looks at Symbicort used as an anti-inflammatory reliever versus short-acting beta2-agonist, the most commonly used reliever therapy today. In biologics, new long-term efficacy and safety data continues to build Fasenra’s clinical profile, and with more than 70 abstracts overall, AstraZeneca is demonstrating its commitment to advancing respiratory science.”
AstraZeneca, at last report, employs 1,500 in Delaware.
